Beam Therapeutics Inc. (BEAM)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
29.32 USD
-1.16
(-3.806%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 29.32 |
Hot Take ↕ | Aug. 22, 2026, 4:19 a.m. EDT
The investment case here is fractured between a speculative short-term catalyst and a deteriorating long-term reality. Fundamentally, the business is in freefall with revenue contracting by nearly 95% and negative operating margins exceeding 250%. The balance sheet, while currently liquid, is burning cash aggressively, and the multi-year price trajectory confirms a structural decline rather than a temporary dip. The stock trades at a premium multiple despite generating no profit, which is a classic value trap in biotech where the market is pricing in a miracle cure that hasn't materialized yet. However, the short-term setup is driven entirely by options speculation and potential binary events. The massive open interest at $50 and $55 strikes suggests traders are waiting for a clinical trial readout or regulatory approval that could double the stock price overnight. Conversely, the heavy put walls at $20-$25 suggest a floor where institutional holders might capitulate. The statistical forecasting model offers no help, showing low confidence and zero directional bias, which aligns with the chaotic nature of a stock trading on hope rather than earnings. For a trader, this is a high-risk momentum play dependent on a specific catalyst; for an investor, the fundamentals are too broken to ignore. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.168693 |
| AutoARIMA | 0.168726 |
| AutoTheta | 0.173551 |
| MSTL | 0.174840 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 4.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.083 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.173 |
| Revenue per Share | 1.511 |
| Market Cap | 3,028,394,240 |
| Forward P/E | -6.18 |
| Beta | 2.21 |
| Profit Margins | -55.45% |
| Website | https://beamtx.com |
As of Aug. 22, 2026, 4:19 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional breakout. Call volume is heavily skewed toward out-of-the-money strikes (50, 55, 5000+ OI), suggesting a speculative bet on a massive rally or binary event, while put writers are establishing heavy walls at lower strikes (20, 25, 22) to cap downside. The implied volatility surface shows extreme spikes at far OTM strikes, indicating the market prices in a 'lottery ticket' scenario where the stock either doubles or crashes, rather than a steady grind higher. The imbalance in open interest favors long gamma exposure at specific levels, creating potential squeeze dynamics if price moves decisively.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8687922 |
| Address1 | 238 Main Street |
| All Time High | 138.522 |
| All Time Low | 13.0 |
| Ask | 37.65 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,796,110 |
| Average Daily Volume3 Month | 2,154,167 |
| Average Volume | 2,154,167 |
| Average Volume10Days | 1,796,110 |
| Beta | 2.209 |
| Bid | 22.01 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 10.685 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 29.32 |
| Current Ratio | 14.572 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 30.49 |
| Day Low | 29.01 |
| Debt To Equity | 23.173 |
| Display Name | Beam Therapeutics |
| Earnings Call Timestamp End | 1,771,938,000 |
| Earnings Call Timestamp Start | 1,771,938,000 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -355,780,992 |
| Ebitda Margins | -2.2801402 |
| Enterprise To Ebitda | -5.69 |
| Enterprise To Revenue | 12.973 |
| Enterprise Value | 2,024,252,544 |
| Eps Current Year | -4.45352 |
| Eps Forward | -4.74137 |
| Eps Trailing Twelve Months | -0.66 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 29.8908 |
| Fifty Day Average Change | -0.5708008 |
| Fifty Day Average Change Percent | -0.019096203 |
| Fifty Two Week Change Percent | 86.87922 |
| Fifty Two Week High | 38.26 |
| Fifty Two Week High Change | -8.939999 |
| Fifty Two Week High Change Percent | -0.23366438 |
| Fifty Two Week Low | 16.02 |
| Fifty Two Week Low Change | 13.299999 |
| Fifty Two Week Low Change Percent | 0.8302122 |
| Fifty Two Week Range | 16.02 - 38.26 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,999,400,000 |
| Float Shares | 88,241,388 |
| Forward Eps | -4.74137 |
| Forward P E | -6.1838665 |
| Free Cashflow | -241,844,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 540 |
| Fullday Change | -1.16 |
| Fullday Change Percent | -3.80577 |
| Fullday Price | 29.32 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -1.61905 |
| Gross Profits | -252,628,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.013730001 |
| Held Percent Institutions | 1.07873 |
| Implied Shares Outstanding | 103,287,665 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. |
| Long Name | Beam Therapeutics Inc. |
| Market | us_market |
| Market Cap | 3,028,394,240 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_564610577 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -86,520,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,150,273,782 |
| Number Of Analyst Opinions | 13 |
| Open | 29.527 |
| Operating Cashflow | -359,376,992 |
| Operating Margins | -258.27142 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 857 327 8775 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 29.32 |
| Post Market Time | 1,787,961,584 |
| Previous Close | 30.48 |
| Price Eps Current Year | -6.5835567 |
| Price Hint | 2 |
| Price To Book | 2.7440336 |
| Price To Sales Trailing12 Months | 19.408428 |
| Profit Margins | -0.55449003 |
| Quick Ratio | 14.254 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -1.16 |
| Regular Market Change Percent | -3.80577 |
| Regular Market Day High | 30.49 |
| Regular Market Day Low | 29.01 |
| Regular Market Day Range | 29.01 - 30.49 |
| Regular Market Open | 29.527 |
| Regular Market Previous Close | 30.48 |
| Regular Market Price | 29.32 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,328,835 |
| Return On Assets | -0.17013 |
| Return On Equity | -0.08184 |
| Revenue Growth | -0.942 |
| Revenue Per Share | 1.511 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 103,287,665 |
| Shares Percent Shares Out | 0.236 |
| Shares Short | 24,374,054 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 23,215,449 |
| Short Name | Beam Therapeutics Inc. |
| Short Percent Of Float | 0.3648 |
| Short Ratio | 13.28 |
| Source Interval | 15 |
| State | MA |
| Symbol | BEAM |
| Target High Price | 80.0 |
| Target Low Price | 26.0 |
| Target Mean Price | 52.15385 |
| Target Median Price | 45.0 |
| Total Cash | 1,152,926,976 |
| Total Cash Per Share | 11.538 |
| Total Debt | 247,358,000 |
| Total Revenue | 156,035,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 28.3029 |
| Two Hundred Day Average Change | 1.0170994 |
| Two Hundred Day Average Change Percent | 0.035936225 |
| Type Disp | Equity |
| Volume | 1,328,835 |
| Website | https://beamtx.com |
| Zip | 2,142 |